Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune surveillance in multiple sclerosis patients treated with natalizumab.

Annals of neurology - 1 May 2006

Stüve Olaf, Marra Christina M, Jerome Keith R, Cook Linda, Cravens Petra D, Cepok Sabine, Frohman Elliot M, Phillips J Theodore, Arendt Gabriele, Hemmer Bernhard, Monson Nancy L, Racke Michael K

Abstract excerpt

OBJECTIVE: Our objective was to test whether natalizumab, an antibody against very late activating antigen (VLA)-4, interferes with central nervous system immune surveillance as assessed by leukocyte cell numbers and cellular phenotypes in cerebrospinal fluid (CSF) and peripheral blood. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD19
Share to CD4 Lymphocyte Count
Share to Immunologic Surveillance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to JC Virus

Share to Leukocyte Count

Share to Lymphocyte Count

Share to Nervous System Diseases

Share to Neutralization Tests

Source

Identifiers

PMID: 16634029
DOI: 10.1002/ana.20858

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-16634029-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune surveillance in multiple sclerosis patients treated with natalizumab.PMID 16634029Read ↗

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation.Semantic proximity Read ↗

Natalizumab effects on immune cell responses in multiple sclerosis.Semantic proximity Read ↗

Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.Semantic proximity Read ↗

A genetic variant of the anti-apoptotic protein Akt predicts natalizumab-induced lymphocytosis and post-natalizumab multiple sclerosis reactivation.Semantic proximity Read ↗

Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.Semantic proximity Read ↗

Fingolimod alters intrathecal B cell maturation in multiple sclerosis patientsSemantic proximity Read ↗

The Enigmatic Role of Viruses in Multiple Sclerosis: Molecular Mimicry or Disturbed Immune Surveillance?Semantic proximity Read ↗

Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.Semantic proximity Read ↗

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.Semantic proximity Read ↗

JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene.Semantic proximity Read ↗

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patientsSemantic proximity Read ↗

Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.